In 2012 a retrospective cohort study, from the University of Alberta, assessed the value of the use of a combination of micronutrients on BMD status of 77 patients over 12 months. Authors did conclude that “combined micronutrient therapy may be a promising alternative to pharmaceutical strategies in order to prevent bone compromise as well as to maintain or to improve BMD” particularly in bisphosphonate resistant patients. The authors also note an important distinction between SrR and SrC forms suggesting that while trials focus on renalate forms, citrate offers some benefit. Highlighting the synthetic ranelic acid (which is almost all excreted within a week) offers no additional benefit as the positive effects on bone are attributed to Sr. With gastric tolerance of strontium in the 25-30% range, the ranelate and citrate forms confer the best bioavailability.
Genuis SJ, Bouchard TP. Combination of Micronutrients for Bone (COMB) Study: bone density after micronutrient intervention. J Environ Public Health. 2012;2012:354151. doi: 10.1155/2012/354151. Epub 2012 Jan 15. PMID: 22291722; PMCID: PMC3265100.